Remove FDA Approval Remove Genetic Engineering Remove In-Vitro Remove Protein
article thumbnail

Brain Awareness Week 2024: A Spotlight on Brain Health and New Treatments for Neurological Diseases

XTalks

This includes discussions on cutting-edge technologies and methodologies in brain research, such as neuroimaging, genetic engineering and artificial intelligence. This relates to neurological conditions like dementia and Alzheimer’s disease, which account for up to 70 percent of dementia cases.

article thumbnail

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

Clinical interest in bsAbs gained momentum following the promising data and market success of blinatumomab (BLINCYTO®, Amgen), a fragment-based bispecific T cell engager (BiTE), which first received FDA approval in 2014 and EMA approval in 2015. Simplified schematic overview of the proposed mechanisms of action for bsAbs.